China Sky One has a history of successfully producing external use drugs and has now set its sights on developing drugs for injection, a market where it sees a great deal of potential. Out of the 11 new drugs currently undergoing clinical trials that are listed below, seven of them are administered by injection:
-- Povidone Iodine Suppository: for treatment of moniliasis colpitis, bacterial colpitis, and hemorrhoids; -- Gabexate Mesylate Injection: for treatment of acute pancreatitis and acute hemorrhagic necrosis of the pancreas; -- Ciclopirox Ointment: for treatment of superficial fungal infection, such as Tinea manuum and Tinea pedis; -- Ciclopirox Olamine Vaginal Suppositories: for treatment of moniliasis, or mycotic colitis. -- Fibrauretnire Suppositories: for treatment of vulvar moniliasis vaginosis; -- Omeprazole Sodium Injection: for treatment of digestive ulcers, gastrinoma, stress ulcers and Reflux Esophagitis. This drug can prevent stress states and upper postoperative digestive tract bleeding and aspiration pneumonitis by general anesthetics; -- Ozagrel Sodium Injection: for treatment of acute cerebral infarction and accompanied impediments; -- Citicoline Sodium Injection: for treatment of acute brain injury and postoperative consciousness impediment; -- Tiopronin Injection: for improving liver function from liver inflammation, fatty liver, alcoholic hepatitis, medication injury, and heavy metal detox. This drug can reduce toxic and side effects of chemotherapy and has a notable curative effect on cataracts and vitreous opacities in early stages -- Carbazochrome Sodium Sulfonate Injection: for treatment of the urinary system, upper digestive tract, respiratory system and obstetric hemorrhage; -- Diltiazem Hydrochloride Injection: for treatment of paroxysmal supraventricular tachycardia and unstable angina pectoris. This drug can also be used for high-blood pressure during an operation or for severe hypertension.
"We are very excited about our pipeline of newly developed drugs," said Mr.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-
looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements can be identified by the use of forward-
looking terminology such as "believe," "expect," "may," "will," "should,"
"project," "plan," "seek," "intend," or "anticipate" or the negative thereof
or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
our future plans, objectives or performance. Actual results could differ
materially from the expectations reflected in such forward-looking statements
as a result of a variety of factors, including the risks associated with the
effect of changing economic conditions in
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Ms. Yanwei Zhang, Board Secretary
Tel: +86-451-53994064
Email: cntiandiren@yahoo.com.cn
Investor Relations Contact:
CCG Elite Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Mr. Richard Micchelli, Financial Writer
Tel: +1-646-454-4516
Email: richard.micchelli@ccgir.com
Web: http://www.ccgelite.com
SOURCE China Sky One Medical, Inc.